MedBiome is a biopharmaceutical company with a novel platform for the identification, screening and development of microbiome modulators. MedBiome harnesses its unique platform to advance the management of inflammatory bowel disease (IBD), Alzheimer's Disease, and colorectal cancer through patients stratification and the development of novel microbiome-targeted therapeutic and nutritional approaches.